The Study to Evaluate the Safety and Efficacy of the Onyx Family
Safety and Efficacy of 1-month Dual Antiplatelet Therapy in High Bleeding and Ischemic Risk Elderly Patients With Coronary Artery Disease After Implantation of Zotarolimus-eluting Coronary Stent System (Onyx Family, Medtronic, Minneapolis, MN); A Multicenter, Prospective, Observational Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Min Ku Chon, MD,PhD
- Phone Number: 82-10-2562-6258
- Email: chonmingu@gmail.com
Study Locations
-
-
Gyeongsangnam-do
-
Yangsan, Gyeongsangnam-do, Korea, Republic of, 50611
- Recruiting
- Pusan National University Yangsan Hospital
-
Contact:
- Min Ku Chon, MD,PhD
- Phone Number: 82-10-2562-6258
- Email: chonmingu@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Aged 75 or more.
- Eligible for interventional procedures.
- Evidence of myocardial ischemia or coronary artery stenosis ≥ 50%.
- Able to take antiplatelets for at least 1 months after the procedure.
- Patients who underwent coronary artery procedures with ZES (Medtronic, Minneapolis, MN, Onyx™ family) stent.
Exclusion Criteria:
- The patient has a known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, zotarolimus, and contrast media (patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine [eg, rash] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled).
- Patients with active pathologic bleeding.
- Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.
- History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia).
- Noncardiac comorbid conditions are present with life expectancy <1 year or that may result in protocol noncompliance (per site investigator's medical judgment).
- Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Aged 75 or more
Elderly patients aged 75 years or older
|
Safety and Efficacy of 1-Month DAPT in Elderly Patients at High Risk of Ischemia and Bleeding After Percutaneous Coronary Intervention with Onyx Family Stents
Other Names:
|
|
Eligible for interventional procedures
"Patients requiring PCI (Percutaneous Coronary Intervention) procedure
|
Safety and Efficacy of 1-Month DAPT in Elderly Patients at High Risk of Ischemia and Bleeding After Percutaneous Coronary Intervention with Onyx Family Stents
Other Names:
|
|
Evidence of myocardial ischemia or coronary artery stenosis ≥ 50%
Patients with evidence of myocardial ischemia or coronary artery stenosis ≥ 50% on coronary angiography
|
Safety and Efficacy of 1-Month DAPT in Elderly Patients at High Risk of Ischemia and Bleeding After Percutaneous Coronary Intervention with Onyx Family Stents
Other Names:
|
|
Able to take antiplatelets for at least 1 months after the procedure
Patients able to take antiplatelets after the procedure
|
Safety and Efficacy of 1-Month DAPT in Elderly Patients at High Risk of Ischemia and Bleeding After Percutaneous Coronary Intervention with Onyx Family Stents
Other Names:
|
|
Patients who underwent coronary artery procedures with ZES stent
Patients who underwent coronary artery procedures with Onyx™ family stent
|
Safety and Efficacy of 1-Month DAPT in Elderly Patients at High Risk of Ischemia and Bleeding After Percutaneous Coronary Intervention with Onyx Family Stents
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
MACCE at 12 months after coronary artery intervention
Time Frame: immediately after the procedure
|
MACCE defined as a composite of all-cause mortality, MI, and cerebrovascular events at 12 months after the index procedure
|
immediately after the procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All-cause mortality
Time Frame: immediately after the procedure
|
All-cause mortality up to 1 year after the procedure
|
immediately after the procedure
|
|
Cardiac mortality
Time Frame: immediately after the procedure
|
Cardiac mortality up to 1 year after the procedure
|
immediately after the procedure
|
|
Myocardial infarction (MI)
Time Frame: immediately after the procedure
|
Myocardial infarction (MI) up to 1 year after the procedure
|
immediately after the procedure
|
|
Cerebrovascular events
Time Frame: immediately after the procedure
|
Cerebrovascular events up to 1 year after the procedure
|
immediately after the procedure
|
|
Target vessel revascularization (TVR)
Time Frame: immediately after the procedure
|
Target vessel revascularization (TVR) up to 1 year after the procedure
|
immediately after the procedure
|
|
Target lesion revascularization (TLR)
Time Frame: immediately after the procedure
|
Target lesion revascularization (TLR) up to 1 year after the procedure
|
immediately after the procedure
|
|
Stent thrombosis (ARC criteria)
Time Frame: immediately after the procedure
|
Stent thrombosis (ARC criteria) up to 1 year after the procedure
|
immediately after the procedure
|
|
Bleeding Academic Research Consortium (BARC) type 2 to 5
Time Frame: immediately after the procedure
|
Bleeding Academic Research Consortium (BARC) type 2 to 5 up to 1 year after the procedure
|
immediately after the procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Min Ku Chon, MD,PhD, Pusan National University Yangsan Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BRONYX STUDY
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.